BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11815671)

  • 1. Nitric oxide as the mediator of the antiosteoporotic actions of estrogen, statins, and essential fatty acids.
    Das UN
    Exp Biol Med (Maywood); 2002 Feb; 227(2):88-93. PubMed ID: 11815671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential fatty acids as possible mediators of the actions of statins.
    Das UN
    Prostaglandins Leukot Essent Fatty Acids; 2001 Jul; 65(1):37-40. PubMed ID: 11487306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefits-is there a common link?
    Das UN
    Nutrition; 2002 Feb; 18(2):178-88. PubMed ID: 11844650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis.
    Herman AG; Moncada S
    Eur Heart J; 2005 Oct; 26(19):1945-55. PubMed ID: 15911567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactive Lipids as Mediators of the Beneficial Actions of Statins.
    Das UN
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):4-8. PubMed ID: 31274836
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide.
    Ma S; Ma CC
    Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans.
    Wimalawansa SJ
    Ann N Y Acad Sci; 2007 Nov; 1117():283-97. PubMed ID: 18056048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide and bone.
    Wimalawansa SJ
    Ann N Y Acad Sci; 2010 Mar; 1192():391-403. PubMed ID: 20392265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats.
    Yin H; Shi ZG; Yu YS; Hu J; Wang R; Luan ZP; Guo DH
    Eur J Pharmacol; 2012 Jan; 674(2-3):200-6. PubMed ID: 22130356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis and atherosclerosis].
    Omura Y; Nishio Y; Kashiwagi A
    Clin Calcium; 2007 Mar; 17(3):346-53. PubMed ID: 17339738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and nitric oxide donors affect thrombospondin 1-induced chemotaxis.
    Seymour K; Stein J; Han X; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2014; 48(7-8):470-5. PubMed ID: 25361959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are cardiovascular disease and osteoporosis directly linked?
    Whitney C; Warburton DE; Frohlich J; Chan SY; McKay H; Khan K
    Sports Med; 2004; 34(12):779-807. PubMed ID: 15462612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide.
    McGown CC; Brookes ZL
    Br J Anaesth; 2007 Feb; 98(2):163-75. PubMed ID: 17251210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.
    Keeble JE; Moore PK
    Br J Pharmacol; 2002 Oct; 137(3):295-310. PubMed ID: 12237248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of statins on endothelium, inflammation and cardioprotection.
    Elrod JW; Lefer DJ
    Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin reduces pulmonary vein spontaneous activity through nitric oxide pathway.
    Hu YF; Chen YC; Cheng CC; Higa S; Chen YJ; Chen SA
    J Cardiovasc Electrophysiol; 2009 Feb; 20(2):200-6. PubMed ID: 18775044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
    Laufs U
    Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.
    Coons JC
    Ann Pharmacother; 2002 Feb; 36(2):326-30. PubMed ID: 11847956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological significance of essential fatty acids.
    Das UN
    J Assoc Physicians India; 2006 Apr; 54():309-19. PubMed ID: 16944615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and osteoporosis: new role for old drugs.
    Jadhav SB; Jain GK
    J Pharm Pharmacol; 2006 Jan; 58(1):3-18. PubMed ID: 16393459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.